Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Launch of LINZESS« Tablets 0.25mg in Japan

03/21/2017 | 09:41pm EDT

Tokyo, March 22, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, 'Astellas') announced that it launched a guanylate cyclase-C (GC-C) receptor agonist, LINZESS Tablets (generic name: linaclotide, 'LINZESS') for irritable bowel syndrome with constipation ('IBS-C') in Japan today.

IBS-C is a functional but not organic disorder which is characterized by abdominal pain and/or discomfort along with abnormal defecation. These gastrointestinal symptoms persist for a long period with frequent remissions and exacerbations.

LINZESS locally binds to the GC-C receptor expressed on the intestinal epithelium. Activation of the GC-C receptor results in improved visceral hypersensitivity, increased intestinal fluid secretion and accelerated intestinal transit. It is estimated that 2.9% of adults in Japan suffer from IBS-C , and, until today, there were no prescription products available in Japan for the treatment of this indication.

Astellas entered into a license agreement with Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD, CEO: Peter Hecht, Ph.D.) in 2009 and was granted exclusive rights to develop and commercialize linaclotide in Japan. Astellas obtained marketing approval for LINZESSin Japan in December 2016 for patients with IBS-C.

Astellas expects that the launch of LINZESS will help patients in Japan who are suffering from IBS-C by providing a new therapeutic option.

Kubo M, Fujiwara Y, Shiba M, Kohata Y, Yamagami H, Tanigawa T, et al. Differences between risk factors among irritable bowel syndrome subtypes in Japanese adults. Neurogastroenterol Motil. 2011;23:249-54.

Brand Name: LINZESS Tablet 0.25 mg

Generic Name: linaclotide

Dosage Form/Content: Tablet containing 0.25 mg of linaclotide

Indication: Irritable bowel syndrome with constipation

Precautions with related to indication:

Application of this drug should be considered for adult patients whose symptom has not improved after dietary guidance and lifestyle guidance as the basics of the treatment for irritable bowel syndrome with constipation are provided.

Dosage and Administration:

The usual adult dosage is 0.5 mg as linaclotide taken orally once daily before eating.

The dosage may be reduced to 0.25 mg depending on the symptoms.

Precautions with related to dosage and administration:

Since occurrence of severe diarrhea is possible, investigators are instructed to evaluate patients' symptoms periodically so that continuous administration of this drug will not be done unthinkingly.

Astellas Pharma Inc. published this content on 22 March 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 March 2017 02:41:17 UTC.


ę Publicnow 2017
All news about ASTELLAS PHARMA INC.
02:12aASTELLAS PHARMA : Science-based Exercise at Home with Fit-eNce HomeTM Pilot Sales Begins T..
PU
09/20ASTELLAS PHARMA : ' and Pfizer's XTANDI« (enzalutamide) Reduced Risk of Death by 34% in Me..
PU
09/20ASTELLAS PHARMA : ' and pfizer's xtandi (enzalutamide) reduced risk of death by 34% in men..
AQ
09/09ASTELLAS PHARMA : Updates “Contact for Potential Acquisition of ' R&D Programs&rdquo..
PU
09/02ASTELLAS PHARMA : Nitto, and M. Heart Partnering for ECG testing service
PU
09/01Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked My..
CI
08/31ASTELLAS PHARMA : Announces Personnel Changes
PU
08/30ASTELLAS PHARMA : Launches its Corporate Website's New Modalities~Approach for Cell..
PU
08/20SECTOR UPDATE : Health Care Stocks Mixed Premarket Friday
MT
08/20FIBROGEN : Receives $120 Million Milestone Payment With Approval of Evrenzo in Europe
MT
More news
Financials
Sales 2022 1 325 B 12 129 M 12 129 M
Net income 2022 194 B 1 780 M 1 780 M
Net cash 2022 478 B 4 372 M 4 372 M
P/E ratio 2022 17,7x
Yield 2022 2,67%
Capitalization 3 476 B 31 819 M 31 823 M
EV / Sales 2022 2,26x
EV / Sales 2023 1,90x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 876,00 JPY
Average target price 2 451,54 JPY
Spread / Average Target 30,7%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.17.69%31 975
JOHNSON & JOHNSON4.09%431 227
ROCHE HOLDING AG10.52%321 941
PFIZER, INC.19.23%247 816
NOVO NORDISK A/S48.69%229 255
ELI LILLY AND COMPANY37.20%210 000